John Evans, Beam Therapeutics CEO

Not yet in the clin­ic, Beam’s base-edit­ed, off-the-shelf CAR-T put on hold

On Fri­day, the FDA slapped a hold on Beam Ther­a­peu­tics’ pre­clin­i­cal off-the-shelf CAR-T ther­a­py, the biotech an­nounced this morn­ing.

At the end of June, the base edit­ing biotech sub­mit­ted its ap­pli­ca­tion to be­gin clin­i­cal tri­als for its CAR-T ther­a­py in pa­tients with re­lapsed/re­frac­to­ry T-cell acute lym­phoblas­tic leukemia and lym­phoma — ag­gres­sive white blood cell can­cers that do not re­spond well to treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.